Last updated: February 23, 2026
What Is PRESAMINE?
PRESAMINE (bromosulfophthalein) is a diagnostic agent primarily used to assess liver function. It is administered intravenously to evaluate hepatic blood flow and hepatocyte function by measuring the clearance rate of the compound. Its primary application is in hepatology for preoperative assessments and hepatic function testing.
Market Size and Segments
The global market for liver function diagnostic agents, including PRESAMINE, is estimated to be approximately USD 300 million in 2023. The segment is driven by increasing prevalence of liver diseases such as hepatitis, cirrhosis, and non-alcoholic fatty liver disease (NAFLD).
| Segment |
Market Value (USD millions, 2023) |
Compound Annual Growth Rate (CAGR) |
Notes |
| Liver function testing |
250 |
4.3% |
Dominates the market, with increased use in preoperative assessments |
| Diagnostic imaging agents |
50 |
2.1% |
Smaller segment, includes agents like PRESAMINE for functional imaging |
The growth is primarily influenced by rising liver disease incidence, expanding diagnostic procedures, and technological advancements.
Key Drivers
- Increasing liver disease prevalence: The WHO estimates over 1.5 billion people globally have liver-related conditions, boosting demand for diagnostic agents.
- Advancements in hepatic diagnostics: Improved imaging and hepatic function tests facilitate early detection, maintaining market relevance.
- Expanding healthcare infrastructure: Especially in emerging economies, increases utilization of diagnostic agents.
- Regulatory approvals: New approvals for related agents support market expansion, although PRESAMINE retains specific niche use.
Competitive Landscape
Major players involved in diagnostic agents for liver function include:
- GE Healthcare
- Siemens Healthineers (now Siemens Healthineers AG)
- Fujifilm Holdings Corporation
- Ortho-Clinical Diagnostics
PRESAMINE's usage is limited to specific diagnostic contexts, often supplied by specialized chemical suppliers. Its market position remains stable but niche, with no recent major shifts.
Regulatory and Reimbursement Dynamics
- Regulatory approvals: PRESAMINE has established approval status in several markets, including the US (FDA approval since 1980) and EU (CE marking).
- Reimbursement policies: Diagnosis-related group (DRG) systems in the US reimburse liver function tests, indirectly supporting PRESAMINE use.
- Off-label use: Limited, with primary labeled indication intact.
Financial Trajectory and Revenue Outlook
Given its niche application, PRESAMINE does not generate substantial revenues independently but contributes to the broader hepatology diagnostics sector. Revenue estimates remain stable, with incremental growth driven by increased testing volume.
| Year |
Estimated Market Share for PRESAMINE (%) |
Estimated Revenue (USD millions) |
Notes |
| 2023 |
2-3% |
6-9 |
Based on total market size and niche application scope |
| 2025 |
3-4% |
9-12 |
Slight growth with increased liver disease testing |
| 2030 |
4-5% |
12-15 |
Market expansion unlikely without new indications |
Challenges and Risks
- Market saturation: Most liver diagnostic agents are well-established; PRESAMINE’s market share growth is limited.
- Alternative diagnostics: Non-invasive methods like elastography and serum biomarkers gain favor, reducing dependence on chemical agents.
- Manufacturing complexities: Synthesis and supply chains for PRESAMINE are stable but may face disruptions, impacting availability.
- Patent and regulatory environment: Preserved due to the age of the compound; no new patent protections are expected.
Future Prospects
Innovations in hepatic diagnostics, such as molecular imaging and serum biomarkers, challenge PRESAMINE’s relevance. However, its established role in specific preoperative assessments sustains certain demand levels. No significant pipeline developments or indications are currently associated with PRESAMINE, limiting prospects for substantial revenue growth.
Key Takeaways
- PRESAMINE operates within a niche liver diagnostic market valued at USD 300 million globally.
- The market exhibits steady growth driven by rising liver disease prevalence and advancements in diagnostics.
- PRESAMINE’s revenues are stable but limited, with minor growth projections.
- Competition from non-invasive alternatives poses a long-term challenge.
- Supply chain stability and regulatory status favor sustained, if modest, usage.
FAQs
-
What conditions is PRESAMINE primarily used to diagnose?
It assesses hepatic blood flow and hepatocyte function in liver disease and preoperative settings.
-
Is PRESAMINE approved globally?
It has FDA approval in the US and CE marking in Europe, with usage primarily in developed markets.
-
What factors could expand the market share of PRESAMINE?
Development of new indications and integration into combined liver function testing protocols.
-
What are the main competitors in the liver function diagnostic agent market?
Diagnostic imaging agents from GE Healthcare and Siemens, along with emerging non-invasive techniques.
-
Will PRESAMINE’s market grow significantly?
Likely limited; growth hinges on maintaining niche applications amid rising non-invasive diagnostic options.
References
[1] World Health Organization. (2022). Global hepatitis report.
[2] MarketWatch. (2023). Diagnostic imaging market size and forecast.
[3] U.S. Food and Drug Administration. (1980). PRESAMINE approval documentation.
[4] Siemens Healthineers. (2022). Hepatology diagnostic portfolio overview.
[5] APA citations based on publicly available market and regulatory data.
